Monitor upcoming quarterly filings for revenue conversion of the increased test volume and for any updates on reimbursement coverage or collection rates.
Drug in focus
BIAF drug pipeline →CyPath Lung
● Neutral Named in this 8-K- Impact
- Phase
- Commercially Available (LDT)
- Time to market
- Already commercially available in the U.S. as a laboratory developed test (LDT) through the company's CLIA-certified lab. CMS reimbursement has been in effect since January 2024.
- Next catalyst
- None dated
What to watchCyPath Lung is already commercial and generating revenue, so the next catalysts are commercial execution metrics (quarterly sales growth, test volumes, physician adoption) and data readouts from the large-scale longitudinal clinical study initiated in March 2026. The stock has fallen ~90% from its 52-week high and recently dipped after Q3 earnings, making sustained sales acceleration the key swing factor for the shares.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 17 $1.93entry
- T+1 · 4d ago +11.40%α +11.70% · $2.15
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
bioAffinity Technologies reported a record 235 CyPath Lung tests performed in October 2026, a 29% increase from October 2025, and equivalent to approximately 45% of Q3 2026 total volume. The company also noted sales team expansion and R&D progress toward applying its platform to asthma and COPD.
Key Facts
- 235 CyPath Lung tests performed in October 2026, a record monthly high
- 29% increase compared with October 2025
- October 2026 volume equal to approximately 45% of total Q3 2026 tests
- Company expanding sales team and working with patient advocacy organizations
- R&D advances in applying technology platform to asthma and COPD
Financial Impact
No revenue or financial figures disclosed; testing volume growth does not directly translate to revenue due to reimbursement variability
Risk Factors
- Historical testing volume does not establish future growth, revenue or profitability
- Reimbursement coverage, payment rates, denials and collection delays could prevent volume growth from translating to revenue
- Variability in monthly testing volume makes trend extrapolation uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-052713 |
| Exhibit: ex99-1.htm | 0001493152-26-052713 |
| Document: 0001493152-26-052713-index-headers.html | 0001493152-26-052713 |
| Document: 0001493152-26-052713-index.html | 0001493152-26-052713 |
| Document: 0001493152-26-052713.txt | 0001493152-26-052713 |
Track record
37 reports on BIAF
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +66.50% at T+60 after the Jul 31, 2026 report. 12 of 16 went positive at some point.
Filters
- Nov 19, 20262d ago SC 13G Neutral 4/10 Entry $2.01 Now $1.65 −17.91% settles Feb 19
- Nov 19, 20262d ago Insider Buy Bullish 5/10 Entry $2.01 Now $1.65 −17.91% settles Feb 19
- Nov 19, 20262d ago 3 Neutral 3/10 Entry $1.85 Now $1.65 −10.81% settles Feb 18
- Nov 19, 20262d ago 8-K Neutral 2/10 Entry $1.85 Now $1.65 −10.81% settles Feb 18
- Nov 17, 20264d ago 8-K Neutral 3/10 Viewing Entry $1.93 Now $1.65 −14.51% settles Feb 16
- Nov 6, 202615d ago 8-K Bearish 5/10 Entry $2.26 Now $1.65 +26.99% settles Feb 5
- Nov 3, 202618d ago 424B5 Bearish 6/10 Entry $2.93 Now $1.65 +43.69% settles Feb 2
- Nov 2, 202619d ago 424B5 Bearish 5/10 Entry $3.19 Now $1.65 +48.28% settles Feb 1
- Oct 29, 202623d ago 8-K Neutral 2/10 Entry $3.03 Now $1.65 −45.54% settles Jan 27
- Oct 23, 202629d ago DEF 14A Neutral 5/10 Entry $2.83 Now $1.65 −41.70% settles Jan 22
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers